Maverick Capital Ltd. Boosts Stock Position in Vaxcyte, Inc. $PCVX

Maverick Capital Ltd. increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 0.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,208,093 shares of the company’s stock after acquiring an additional 6,195 shares during the period. Maverick Capital Ltd.’s holdings in Vaxcyte were worth $45,618,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new stake in shares of Vaxcyte in the 1st quarter valued at about $219,000. Royal Bank of Canada raised its position in Vaxcyte by 115.2% during the 1st quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock valued at $1,113,000 after purchasing an additional 15,774 shares during the last quarter. Paradigm Biocapital Advisors LP raised its position in Vaxcyte by 19.2% during the 1st quarter. Paradigm Biocapital Advisors LP now owns 1,696,481 shares of the company’s stock valued at $64,059,000 after purchasing an additional 273,694 shares during the last quarter. Twin Tree Management LP raised its position in Vaxcyte by 301.3% during the 1st quarter. Twin Tree Management LP now owns 2,365 shares of the company’s stock valued at $89,000 after purchasing an additional 3,540 shares during the last quarter. Finally, Baird Financial Group Inc. raised its position in Vaxcyte by 21.4% during the 1st quarter. Baird Financial Group Inc. now owns 14,299 shares of the company’s stock valued at $540,000 after purchasing an additional 2,523 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Price Performance

PCVX opened at $30.79 on Monday. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of -7.49 and a beta of 1.04. The business has a 50 day simple moving average of $33.34 and a two-hundred day simple moving average of $42.17.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the previous year, the company earned ($1.10) earnings per share. As a group, sell-side analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.